STAT

Opinion: Is there a conflict of interest behind your cancer diagnosis?

Relatively few people explore their pathologist's financial conflicts of interest. More should do that: 1 in 4 pathologists gets payments from industry.

My mother was astonished when I told her about the national Open Payments database that was launched by the Affordable Care Act. “You mean I can see all the money drug companies have given to a doctor? Even my doctor?” We plugged her doctor’s name into the database and up it popped, associated with a number of payments. He had recently prescribed an expensive, brand-name drug for my mother; she had questioned whether a cheaper, older alternative might be just as good. It turned out that her doctor had received payments from the company producing that brand-name drug.

I don’t know, of course, if her doctor’s recommendation had been influenced by these payments or if his choice

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks